HKEX Insight

Introduced in April 2018, Chapter 18A gave pre-revenue and R&D-driven biotech innovators a route to public capital in Hong Kong.

The results are telling: since 2018, 86 companies have listed under the framework raising more than US$17.8 billion. Their combined market capitalisation exceeded US$185 billion as 14 April 2026, according to HKEX data.

Chapter 18A, and latterly Chapter 18C, have helped create diverse channels for biotech companies to list at different stages, helping biotech evolve from individual IPOs into a listed sector that now supports benchmarks, ETFs and derivatives that facilitate secondary‑market liquidity and broader investor participation.

A sector becomes more accessible once it has sufficient breadth to support multiple market uses.

With more than 276 biotech and healthcare-related companies listed on HKEX with a combined market capitalisation of over HK$5 trillion as at April 2026, Hong Kong’s pool of listed biotech names is no longer only about early-stage therapeutic companies, it includes late‑stage drug developers, platform‑technology businesses, AI‑enabled discovery firms and biologics manufacturers.

That maturation is visible at the index level.

While Chapter 18A opened the door for pre revenue companies, many have since progressed: today, only 5% of the Hang Seng Biotech Index by weight is pre revenue, with 95% accounted for by companies that have already reached commercialisation, illustrating how listings have evolved over time and why the sector can now support benchmarks, ETFs and derivatives at scale.

Structural change in the Chinese Mainland biotech ecosystem has helped expand the depth and diversity of the listed universe.

Now, Chinese Mainland biotech companies are expanding and producing a broader range of novel treatments. And, as capabilities deepen at home, a growing number are pursuing internationalisation strategies through out‑licensing and cross‑border partnerships.

According to NextPharma, the total value of out-licensing transactions involving drugs originating from the Chinese Mainland reached US$136 billion in 2025.

A Nature Biotechnology analysis said companies based in the Chinese Mainland participated in six of the top 10 R&D out licensing partnerships, including the year’s largest.

And, as of 15 February 2026, 39 out-licensing deals involving Chinese Mainland companies were recorded year-to-date with a combined value exceeding US$49 billion, representing more than 30% of 2025 full‑year activity.

The breadth and depth of the biotech issuer base in Hong Kong is not only about therapeutic areas; it is also about where companies sit in the value chain, and the ecosystem includes a cluster of listed infrastructure and platform providers spanning biologics contract manufacturing, viral vector and plasmid production, preclinical research and cell-and-gene-therapy manufacturing.

These companies operate deeper in the biotech value chain, with revenues linked to services rather than individual trial outcomes. Moreover, as Chinese Mainland biotech firms increasingly out-license assets to global pharmaceutical partners, demand is rising for internationally compliant manufacturing and research services, and Hong Kong hosts listed infrastructure providers operating in these segments.

As platforms become more data‑rich and transparent, public markets themselves become a form of discovery, and HKEX's rigorous disclosure standards are increasingly referenced by global pharmaceutical companies evaluating partnership opportunities and assessing disclosed pipelines and development data.

While many equity sectors are driven primarily by earnings, Hong Kong biotech is also shaped by scientific and regulatory milestones. Clinical trial readouts, regulatory approval decisions, and announcements are binary, dateable events. Unlike revenue surprises, they are typically discrete, date‑specific events.

Over time, a growing community of analysts, traders and portfolio managers in Hong Kong has built its strategy explicitly around the biotech calendar, coinciding with the increased use of event‑driven strategies supported by structured products.

Between January 2025 and March 2026, the total number of derivatives warrants and callable bull/bear contract (CBBCs) linked to constituent companies within the Hang Seng Biotech Index (HSBIO) increased from 132 to 484 – average daily turnover of those instruments linked to HSBIO constituents reached HK$142 million in March 2026, according to HKEX data.

The rise of biotech single stock options has further reinforced Hong Kong’s event driven trading culture. As of March 2026, 10 Hang Seng Biotech Index (HSBIO) constituents were option eligible, allowing investors to express targeted views around clinical data releases and regulatory decisions at the individual stock level.

Aggregate average daily turnover notional reached HK$614 million in March 2026, highlighting how options have become a preferred tool for managing binary risk alongside structured products in an increasingly event rich biotech universe.

Biotech ETFs have emerged as a tool for investors seeking broad exposure to the sector without the risks of single-stock concentration.

Investor interest has grown significantly, with assets under management in Hong Kong-listed biotech ETFs tracking HSBIO rising from HK$1.5 billion in March 2021 to HK$12 billion by end-March, and turnover growing from HK$14.3 million to HK$1.97 billion over the same period. This growth reflects both increased product availability and a supportive market environment.

Beyond access and diversification, biotech ETFs also play a strategic role in market development. By anchoring benchmark-based flows, they help reinforce liquidity in the underlying sector and lay the groundwork for further product innovation, including structured products and active strategies.

Futures contracts are a key part of Hong Kong’s product infrastructure. The launch of Hang Seng Biotech Index Futures on 28 November 2025 marked a further step in the development of the city’s listed biotech market, extending the ecosystem beyond the cash market to provide an additional risk management and price reference tool.

Uptake has been steadily building: the contracts hit a record high of 1,239 contracts on 27 March 2026, according to HKEX data, as market participants increasingly look to manage exposure to Hong Kong’s biotech ecosystem.

Across the pipelines of many Hong Kong-listed companies sit many of the technologies likely to define medicine over the next decade, but what distinguishes Hong Kong is that these innovations are public, comparable and tradable.

What began as a listing framework has evolved into a multi‑asset biotech market supporting capital formation, secondary trading and risk management. Benchmarks, ETFs, structured products, and sector futures have turned biotech from a niche listing category into a liquid, analysable asset class.

In doing so, Hong Kong has become a shop window for innovation – where scientific progress is continuously translated into market signals. And as biotech globalises and accelerates, HKEX is where innovation has become investible.